Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial
Pfizer’s recently acquired weight loss injection has shown to maintain weight loss after a switch from weekly to monthly dosing…
Metabolic Disorders
-
-
Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial
Novo Nordisk’s CagriSema has outperformed the company’s flagship type 2 diabetes drug Ozempic (semaglutide) in both HbA1c levels and weight…
-
Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial
Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound (tirzepatide) has shown benefit in interim…
-
MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial
MetaVia’s dual oxyntomodulin (OXM) analogue agonist has met the endpoints in a Phase Ib trial evaluating the drug for weight…
-
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4…
-
Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes
Novo Nordisk is advancing its amylin agonist, amycretin, to Phase III in type 2 diabetes (T2D) after the drug met…
-
Innovent boasts another pivotal trial success for obesity drug
Innovent Biologics’ obesity drug has shown success in another pivotal trial, meeting the primary and all key secondary endpoints. In…
-
Eledon’s transplant rejection drug shows promise in Phase I/II diabetes trial
Eledon Pharmaceuticals’ drug to prevent islet transplantation rejection in type 1 diabetes has led to an insulin-free life in patients…
-
Lilly to advance alternative obesity candidate to Phase III
Eli Lilly is advancing its obesity treatment candidate, which is an alternative to glucagon-like peptide-1 receptor agonists (GLP-1RAs), to Phase…
-
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by…
